WACKER’s New Process-Development Unit Focusses on ESETEC® and Supplies First Customers with Double-Digit Gram Quantities of Biologics for Preclinical Development
News Apr 01, 2009
The new unit has already started shipping to customers. WACKER is thereby optimizing the entire process-development chain, from gene to purified protein. The new unit can now ship double-digit gram quantities of highly pure proteins for pre-clinical development, prior to scale-up in the GMP plant. The infrastructure of the new building has been specifically designed to cater for the sophisticated process and analytics development necessitated by modern biologics based on microbial systems. The extension is WACKER’s response to fast-growing demand for ESETEC®, its E. coli secretion technology. This proprietary technology can be used to simplify and streamline production of a successful new class of biotherapeutics called antibody fragments in high yield.
WACKER is substantially boosting production capacity at its Jena site in order to cope with a growing need for high-efficiency biologics production and to meet rising customer demand. Covering some 1.700 m2, the recently completed building is dedicated to process development and protein analysis along the entire process chain, from gene to highly pure protein. The equipment used for fermentation (capacities up to 30 liters), primary processing (centrifugation, filtration, homogenization), downstream processing and protein modification (e.g. PEGylation) is designed to allow the processes to be upscaled to WACKER’s GMP production. The latest principles of quality-by-design (QbD) are observed throughout process development, and necessitate detailed prior knowledge of products and processes.
Aside from the actual process laboratories, the new unit boasts modern analytical laboratories for safeguarding the development of methods of process and product characterization right through to GMP analysis. As a result, Wacker Biotech GmbH will fully and optimally satisfy approval agencies’ standards for ever stricter analytical characterization of products and processes. The full range of analytical tools is available: from biochemical assays to chromatography, electrophoresis, photometry, protein sequencing, and spectroscopy, through to trace analysis of impurities (DNA, HCP, en-dotoxins). Customers thus take delivery of a full process and analysis package provided by a single source.
Traditional production methods aside, one focus of the new unit is on ESETEC® and DENSETEC®, which are proprietary WACKER technologies that make for simpler, more cost-efficient, high-yield production of biologics for the pharmaceuticals industry. ESETEC® is based on a patented E.coli K12 strain, which is employed during fermentation to secrete recombinant proteins into the culture broth in native conformation. Such extra-cellular production facilitates cleanup of recombinant products and eliminates the complicated backfolding stage. The net effect is to render production much more efficient and more cost-effective.
The ability to combine ESETEC® secretion technology with DENSETEC®, a special high-cell-density process for fermenting E.coli, gives Wacker Biotech the capacity to produce active biologics both efficiently and in optimized space-time yields. These robust, validatable fermentation processes afford products in high, reproducible yields.
A second extension at the Jena site will double the production area in the existing GMP plant and include a brand new downstream processing facility. It will satisfy the US Food and Drug Administration’s GMP requirements, as well as those of the European Medicines Agency. This extension will likely come on full stream in early 2010.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018